@im041989 Profile picture

Mushtaq Ahmad™

@im041989

📖📚🇵🇰🥼🩺🫀

Joined September 2015

We can try till death,


Mushtaq Ahmad™ Reposted

The results of this trial echo those of the WOEST Trial, published 4 years prior

Tweet Image 1
Tweet Image 2

Tension (plus)=qiamat (plus) Never ending


Mushtaq Ahmad™ Reposted

SGLT2 inhibition for HFpEF? This trial showed SGLT2 inhibitors to have mortality benefit with EF > 40%, regardless of diabetes status. HFpEF represents a population of patients that beyond diuretic use, has historically been difficult to treat. DELIVER Trial, NEJM 2022 ♥️ #meded

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

The beta blockers we use in HFrEF: 1. Carvedilol (COPERNICUS Trial) 2. Metoprolol succinate - NOT tartrate! (MERIT-HF Trial) 3. Bisoprolol (CIBIS II Trial) ... each with its respective trial included, in the app 📲 apps.apple.com/us/app/cardiac…


Mushtaq Ahmad™ Reposted

VT vs SVT with aberrancy 🤜🤛, a July #FIT review Yet to come across a better figure👇 #CardioTwitter

Tweet Image 1

Mushtaq Ahmad™ Reposted

Pakistan Air Force salutes the resolve of the entire Pakistani nation on YOUM-E-TAKBEER 25 years since conduct of nuclear tests by #Pakistan marking historic day of #YoumeTakbeer @DGPR_PAF @OfficialDGISPR #PAF #PakistanArmy #ISPR


Mushtaq Ahmad™ Reposted

Peaceful CoExistence General Syed Asim Munir, COAS, “We want to share peace with all, however, our efforts for peace should never be taken as a sign of weakness” #ISPR @OfficialDGISPR #PakistanArmy #Pakistan #COAS


Mushtaq Ahmad™ Reposted

📌#Iron Deficiency in #HeartFailure: A Scientific 📝 from the @HFSA #CardioTwitter #CardioEd #PositionPaper

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Mushtaq Ahmad™ Reposted

Pulmonary Vein Doppler 📚📖 We can glean a surprising amount of information from the pulmonary vein flow alone.. don’t ignore the pulmonary veins 👇 #echofirst ♥️

Tweet Image 1

Mushtaq Ahmad™ Reposted

DOACs for rheumatic atrial fibrillation? This trial showed INCREASED mortality and stroke/thromboembolism when compared to warfarin, our standard of care. A trial in support of current guidelines for vitamin K antagonism in this population. INVICTUS Trial, NEJM 2022 ♥️ #MedEd

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

Why don’t we routinely use antiarrhythmics to suppress ectopy after myocardial infarction? Why are class 1C antiarrhythmics contraindicated in those with coronary artery disease or structural heart disease? Both answers stem from this historic trial. CAST I Trial, NEJM 1991 ♥️

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

SGLT2 Inhibition for HFrEF? Landmark trial showing mortality reduction regardless of diabetes status. Originally a diabetes drug — now with proven cardiovascular and renal protective effects. EMPEROR-Reduced Trial, NEJM 2020 ♥️ #MedEd #MedTwitter

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

The only proven medication which decreases mortality in HFrEF is SGLT2 inhibitor

SGLT2 inhibition for HFpEF?👇The first positive study with a hint of mortality reduction in HFpEF. Prior studies have largely been negative, with the notable exception of TOPCAT, wherein spironolactone showed hospitalization reduction alone. EMPEROR-Preserved Trial, NEJM 2021 ♥️

Tweet Image 1
Tweet Image 2


Mushtaq Ahmad™ Reposted

Classic P2 resection with a sliding plasty for mitral valve insufficiency. Durable repair when used with a ring. Remember to use an upsized or eusized ring! Don’t downsize it. #mitral repair #cardiacsurgery

Tweet Image 1
Tweet Image 2
Tweet Image 3

Mushtaq Ahmad™ Reposted

Ivabradine for heart failure? Ivabradine (an I “funny” channel blocker that slows the sinus node) can be used as add-on therapy for patients with HFrEF in whom target heart rates cannot be reached… despite maximization of beta blockade. SHIFT Trial, Lancet 2010 ♥️ #CardioTwitter

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

SGLT2 inhibition for HFpEF? This trial showed SGLT2 inhibitors to have mortality benefit with EF > 40%, regardless of diabetes status. HFpEF represents a population of patients that beyond diuretic use, has historically been difficult to treat. DELIVER Trial, NEJM 2022 ♥️ #meded

Tweet Image 1
Tweet Image 2

Mushtaq Ahmad™ Reposted

2023 ACC Expert Consensus Decision Pathway on Management of #HFpEF @ACCinTouch Solution Set Oversight Committee 👉Diagnosis 👉Management HFpEF 👉 Multidisciplinary Considerations in HFpEF 📥jacc.org/doi/10.1016/j.…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Mushtaq Ahmad™ Reposted

Addressing the underlying cause of pulmonary arterial hypertension? Unlike traditional therapies like PDE5 inhibitors which simply vasodilate, sotatercept remodels the pulmonary vascular bed itself👇— now with proven mortality benefit. STELLAR Trial, NEJM 2023 ♥️ #CardioEd #meded

Tweet Image 1
Tweet Image 2

United States Trends
Loading...

Something went wrong.


Something went wrong.